Tackling Undruggable Cancer Targets using Chemoproteomic Platforms
- Institution
- UNIVERSITY OF CALIFORNIA BERKELEY, CA
- Principal investigator
- Daniel Nomura
- Funding
- $928K
- Duration
- 2022–2029
Moonbase score
Still being scored
Abstract
One of the biggest challenges facing cancer drug discovery is that >90 % of the proteome is currently considered “undruggable” because most proteins do not possess known binding pockets or “ligandable hotspots” that can be pharmacologically and functionally targeted for therapeutic benefit 1. Tackling the undruggable proteome requires the development of innovative technologies for ligand discovery AND the discovery of novel therapeutic modalities to functionally manipulate the undruggable proteome for therapeutic benefit. The Nomura Research Group is focused on reimagining druggability by advancing and applying chemoproteomic platforms to tackle the undruggable proteome, towards developing next-generation therapies and therapeutic modalities for cancer.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CALIFORNIA BERKELEY
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California BerkeleyNot yet scored
Harnessing E3 Ligases for Cancer Therapy
Daniel Nomura · $388K · 2019–2029
- NIH · University of California Berkeley48
Leveraging Single Cell Stimulation to Untangle Parallel Perceptual Pathways in the Human Retina
Leah Johnston · $47K · 2024–2027
- NIH · University of California Berkeley48
Discovery and Development of Organic Reactions Catalyzed by Transition Metals Valuable for Medicinal Chemistry
John F Hartwig · $832K · 2019–2027